ARCA biopharma Announces IND Submission to FDA for Gencaro for the Treatment of Atrial Fibrillation

Published: Oct 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the GENETIC-AF clinical trial of Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment.

Help employers find you! Check out all the jobs and post your resume.

Back to news